Teva’s 44-Week Trial Shows Up to 58% Remission, Shares Rally 2.85%
RELIEVE UCCD extension study ran 44 weeks demonstrating 58% clinical remission in ulcerative colitis at 900 mg and 47% at 450 mg, with 55% and 41% endoscopic responses in Crohn’s patients. Teva shares rose 2.85% premarket as Goldman Sachs, Barclays and Scotiabank lifted price targets to $45, $38 and $40.
1. RELIEVE UCCD Extension Study Data
The RELIEVE UCCD long-term extension evaluated subcutaneous doses of 450 mg and 900 mg duvakitug every four weeks for up to 58 weeks in 130 patients who responded during induction. At week 44, 58% of the 900 mg cohort and 47% of the 450 mg cohort maintained clinical remission in ulcerative colitis, while 55% and 41% of corresponding cohorts in Crohn’s disease achieved endoscopic response. Both doses were well tolerated across additional efficacy measures.
2. Share Performance and Analyst Upgrades
Teva shares advanced 2.85% in premarket trading following the study results, reflecting investor enthusiasm for durable IBD treatment data. Goldman Sachs, Barclays and Scotiabank raised their price targets to $45, $38 and $40 respectively, maintaining Buy or Outperform ratings based on the drug’s commercial implications.